{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:31:09Z","timestamp":1793421069925,"version":"4.5.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003141","name":"Secretar\u00eda de Ciencia, Humanidades, Tecnolog\u00eda e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["CVU Number: 1084504"],"award-info":[{"award-number":["CVU Number: 1084504"]}],"id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.canep.2026.103227","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T09:59:31Z","timestamp":1788343171000},"page":"103227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comorbidities in patients with lymphoma and their impact on clinical outcomes: A narrative review"],"prefix":"10.1016","volume":"105","author":[{"given":"Junice Teresita","family":"Sosa-Romero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gladys Patricia","family":"Agreda-V\u00e1squez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilia","family":"Castillo-Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canep.2026.103227_bib1","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK\u2019s Haematological Malignancy Research Network","volume":"112","author":"Smith","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canep.2026.103227_bib2","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/17474086.2017.1281122","article-title":"Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic\/dendritic cell neoplasms","volume":"10","author":"Jiang","year":"2017","journal-title":"Expert. Rev. Hematol."},{"key":"10.1016\/j.canep.2026.103227_bib3","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse Large B-Cell Lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.canep.2026.103227_bib4","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.canep.2026.103227_bib5","doi-asserted-by":"crossref","unstructured":"Porta, Miquel, A Dictionary of Epidemiology, 2014.","DOI":"10.1093\/acref\/9780199976720.001.0001"},{"key":"10.1016\/j.canep.2026.103227_bib6","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/annonc\/mdx413","article-title":"ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma","volume":"29","author":"Buske","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canep.2026.103227_bib7","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/ajh.24819","article-title":"Impact of comorbidities on outcomes of elderly patients with diffuse large B-cell lymphoma","volume":"92","author":"Saygin","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.canep.2026.103227_bib8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00277-017-3170-z","article-title":"Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B cell lymphoma? The prognostic significance of comorbidities","volume":"97","author":"Antic","year":"2018","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.canep.2026.103227_bib9","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/joim.12849","article-title":"Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma: a Swedish lymphoma register study","volume":"285","author":"W\u00e4sterlid","year":"2019","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.canep.2026.103227_bib10","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1001\/jama.291.20.2441","article-title":"Prognostic Importance of Comorbidity in a Hospital-Based Cancer Registry","volume":"291","author":"Piccirillo","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.canep.2026.103227_bib11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"issue":"8","key":"10.1016\/j.canep.2026.103227_bib12","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.canep.2026.103227_bib13","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0959-8049(99)00319-6","article-title":"Measuring comorbidity in older cancer patients","volume":"36","author":"Extermann","year":"2000","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canep.2026.103227_bib14","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3109\/02813432.2016.1153242","article-title":"The role of diseases, risk factors and symptoms in the definition of multimorbidity \u2013 a systematic review","volume":"34","author":"Willadsen","year":"2016","journal-title":"Scand. J. Prim. Health Care"},{"key":"10.1016\/j.canep.2026.103227_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2022-000247","article-title":"Measuring multimorbidity in research: Delphi consensus study","volume":"1","author":"Ho","year":"2022","journal-title":"BMJ Med."},{"key":"10.1016\/j.canep.2026.103227_bib16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/hematology.2019000028","article-title":"Management of older Hodgkin lymphoma patients","volume":"2019","author":"Evens","year":"2019","journal-title":"Hematology"},{"key":"10.1016\/j.canep.2026.103227_bib17","doi-asserted-by":"crossref","first-page":"921","DOI":"10.3109\/10428194.2014.953142","article-title":"M. Spina, Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL)","volume":"56","author":"Tucci","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.canep.2026.103227_bib18","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canep.2026.103227_bib19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2141.2011.09011.x","article-title":"Treatment of the elderly patient with diffuse large B cell lymphoma","volume":"157","author":"Fields","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canep.2026.103227_bib20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3816\/CLML.2010.n.004","article-title":"Brief-Duration Rituximab\/Chemotherapy Followed by Maintenance Rituximab in Patients With Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy: A Phase II Trial of the Sarah Cannon Oncology Research Consortium","volume":"10","author":"Hainsworth","year":"2010","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.canep.2026.103227_bib21","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1586\/17474086.2015.1024650","article-title":"Impact of comorbidities on the treatment of non-Hodgkin\u2019s lymphoma: a systematic review","volume":"8","author":"Terret","year":"2015","journal-title":"Expert. Rev. Hematol."},{"key":"10.1016\/j.canep.2026.103227_bib22","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","volume":"403","author":"GBD 2021 Diseases and Injuries Collaborators","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.canep.2026.103227_bib23","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.3390\/ijerph17124242","article-title":"Multimorbidity Patterns in the General Population: Results from the EpiChron Cohort Study","volume":"17","author":"Ioakeim-Skoufa","year":"2020","journal-title":"Int. J. Environ. Res. Public. Health"},{"key":"10.1016\/j.canep.2026.103227_bib24","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S0140-6736(20)32000-6","article-title":"Offline: COVID-19 is not a pandemic","volume":"396","author":"Horton","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.canep.2026.103227_bib25","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","article-title":"Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety","volume":"36","author":"Hiddemann","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canep.2026.103227_bib26","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin\u2019s Lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.canep.2026.103227_bib27","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.canep.2026.103227_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70800","article-title":"Comparison of Mortality Rates Between Patients With Diffuse Large B Cell Lymphoma Surviving 5\u2009Years After Initial Diagnosis and a Matched General Population Cohort","volume":"14","author":"Acquavella","year":"2025","journal-title":"Cancer Med."},{"key":"10.1016\/j.canep.2026.103227_bib29","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2340\/1651-226X.2025.42539","article-title":"Population based registry study on large B-cell lymphoma mortality and morbidity in Finland","volume":"64","author":"Anttalainen","year":"2025","journal-title":"Acta Oncol."},{"key":"10.1016\/j.canep.2026.103227_bib30","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1002\/cncr.31981","article-title":"A population-based multistate model for diffuse large B-cell lymphoma\u2013specific mortality in older patients","volume":"125","author":"\u00c7a\u011flayan","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.canep.2026.103227_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/hon.70137","article-title":"Adaptation and Performance of the Self-Report-Generated Charlson Comorbidity Index in the Lymphoma Epidemiology of Outcomes (LEO) Cohort","volume":"43","author":"Cerhan","year":"2025","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.canep.2026.103227_bib32","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1002\/cncr.30173","article-title":"Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma","volume":"122","author":"Chihara","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.canep.2026.103227_bib33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00277-022-05018-z","article-title":"Performance status, comorbidities, and cycles of methotrexate exert the greatest influence on outcomes of primary and secondary CNS lymphomas: the Lexington experience","volume":"102","author":"Curry","year":"2023","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.canep.2026.103227_bib34","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.2217\/fon-2018-0596","article-title":"Effects Of Center Type and Socioeconomic Factors On Early Mortality And Overall Survival of Diffuse Large B-Cell Lymphoma","volume":"15","author":"Dhakal","year":"2019","journal-title":"Future Oncol."},{"key":"10.1016\/j.canep.2026.103227_bib35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/hon.2428","article-title":"Impact of comorbidity on survival in peripheral T-cell lymphomas: A Swedish Lymphoma Registry study","volume":"36","author":"Ellin","year":"2018","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.canep.2026.103227_bib36","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","article-title":"Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma","volume":"36","author":"Evens","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canep.2026.103227_bib37","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/hon.2715","article-title":"Comorbidity assessment to determine prognosis in older adult patients with classical Hodgkin lymphoma","volume":"38","author":"Galli","year":"2020","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.canep.2026.103227_bib38","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/bjh.16317","article-title":"Comorbidities and sex differences in causes of death among mantle cell lymphoma patients \u2013 A nationwide population-based cohort study","volume":"189","author":"Glimelius","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canep.2026.103227_bib39","doi-asserted-by":"crossref","DOI":"10.1200\/CCI.23.00223","article-title":"Comparison of Comorbidity Models Within a Population-Based Cohort of Older Adults With Non-Hodgkin Lymphoma","author":"Gordon","year":"2024","journal-title":"JCO Clin. Cancer Inform."},{"key":"10.1016\/j.canep.2026.103227_bib40","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1080\/10428194.2023.2256908","article-title":"Influence of treatment intensity and medical comorbidities in older adults with peripheral T cell lymphoma","volume":"64","author":"Gordon","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.canep.2026.103227_bib41","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/bloodadvances.2022009507","article-title":"A novel comorbidity score for older adults with non-Hodgkin lymphoma: the 3-factor risk estimate scale","volume":"7","author":"Gordon","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.canep.2026.103227_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2022.10.011","article-title":"An evaluation based on relative treatment intensity in older patients treated with reduced-dose R-THP-COP therapy for diffuse large B-cell lymphoma: A multicenter retrospective cohort study","volume":"14","author":"Hiroi","year":"2023","journal-title":"J. Geriatr. Oncol."},{"key":"10.1016\/j.canep.2026.103227_bib43","doi-asserted-by":"crossref","first-page":"988","DOI":"10.4149\/neo_2015_120","article-title":"Enhanced International Prognostic Index (NCCN-IPI), Charlson Comorbidity Index and absolute lymphocyte count as predictors for survival of elderly patients with diffuse large B cell lymphoma treated by immunochemotherapy","volume":"62","author":"Jelicic","year":"2015","journal-title":"Neoplasma"},{"key":"10.1016\/j.canep.2026.103227_bib44","doi-asserted-by":"crossref","DOI":"10.1177\/10732748221124865","article-title":"Prognostic Factors for Clinical Outcomes in Patients with Newly Diagnosed Advanced-stage Hodgkin Lymphoma: A Nationwide Retrospective Study","volume":"29","author":"Jerry Teng","year":"2022","journal-title":"Cancer Control."},{"key":"10.1016\/j.canep.2026.103227_bib45","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00277-016-2597-y","article-title":"Peripheral T cell lymphomas in elderly patients: a retrospective analysis from the Hematology Association of South East Korea (HASEK)","volume":"95","author":"Jo","year":"2016","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.canep.2026.103227_bib46","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.3390\/jcm9041005","article-title":"The Prognostic Impact of Comorbidities in Patients with De-Novo Diffuse Large B-Cell Lymphoma Treated with R-CHOP Immunochemotherapy in Curative Intent","volume":"9","author":"Kocher","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.canep.2026.103227_bib47","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1016\/S2352-3026(23)00094-7","article-title":"Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: a population-based study","volume":"10","author":"Kuczmarski","year":"2023","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.canep.2026.103227_bib48","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s00277-016-2768-x","article-title":"R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma","volume":"95","author":"Laribi","year":"2016","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.canep.2026.103227_bib49","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/bjh.16743","article-title":"Prognostic utility of a geriatric nutritional risk index in combination with a comorbidity index in elderly patients with diffuse large B cell lymphoma","volume":"192","author":"Lee","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canep.2026.103227_bib50","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/bloodadvances.2021004269","article-title":"Impact of comorbidity in older patients with peripheral T-cell lymphoma: an international retrospective analysis of 891 patients","volume":"6","author":"Mead","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.canep.2026.103227_bib51","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s12185-016-2099-7","article-title":"FCG (FLIPI, Charlson comorbidity index, and histological grade) score is superior to FLIPI in advanced follicular lymphoma","volume":"104","author":"Mihaljevic","year":"2016","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.canep.2026.103227_bib52","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1634\/theoncologist.2016-0260","article-title":"A Host-Dependent Prognostic Model for Elderly Patients with Diffuse Large B-Cell Lymphoma","volume":"22","author":"Miura","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.canep.2026.103227_bib53","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s00277-021-04470-7","article-title":"Age and comorbidity are determining factors in the overall and relative survival of patients with follicular lymphoma","volume":"100","author":"Mozas","year":"2021","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.canep.2026.103227_bib54","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3960\/jslrt.56.43","article-title":"Retrospective Analysis of Treatment Outcomes and Geriatric Assessment in Elderly Malignant Lymphoma Patients","volume":"56","author":"Naito","year":"2016","journal-title":"J. Clin. Exp. Hematop."},{"key":"10.1016\/j.canep.2026.103227_bib55","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1080\/10428194.2019.1639166","article-title":"Clinical features and survival of patients with T-cell\/histiocyte-rich large B-cell lymphoma: analysis of the National Cancer Data Base","volume":"60","author":"Ollila","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.canep.2026.103227_bib56","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.4103\/njcp.njcp_175_23","article-title":"The Prognostic Impact of Comorbidity, Nutritional and Performance Status on Patients with Diffuse Large B Cell Lymphoma","volume":"26","author":"Sa\u011flam","year":"2023","journal-title":"Niger. J. Clin. Pract."},{"key":"10.1016\/j.canep.2026.103227_bib57","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1097\/SAP.0000000000004434","article-title":"Primary Cutaneous Follicle Center Lymphoma","volume":"95","author":"Taghizadeh","year":"2025","journal-title":"Ann. Plast. Surg."},{"key":"10.1016\/j.canep.2026.103227_bib58","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1007\/s00277-020-04267-0","article-title":"Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed\/refractory diffuse large B cell lymphoma with severe comorbidities","volume":"99","author":"Tanaka","year":"2020","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.canep.2026.103227_bib59","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/joim.12849","article-title":"Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma: a Swedish lymphoma register study","volume":"285","author":"W\u00e4sterlid","year":"2019","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.canep.2026.103227_bib60","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1007\/s00432-020-03279-7","article-title":"Impact of comorbidity and relative dose intensity on outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP","volume":"146","author":"Yamamoto","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.canep.2026.103227_bib61","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0140-6736(21)02143-7","article-title":"Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic","volume":"398","author":"COVID-19 Mental Disorders Collaborators","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.canep.2026.103227_bib62","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/bjh.17384","article-title":"The use of frailty assessments in treating older adults with aggressive lymphomas","volume":"194","author":"Cordoba","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canep.2026.103227_bib63","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.2340\/1651-226X.2025.44776","article-title":"Continuous tobacco smoking increases mortality in diffuse large B-cell lymphoma but not follicular lymphoma, a Finnish population-based study","volume":"64","author":"Reunamo","year":"2025","journal-title":"Acta Oncol."},{"issue":"11","key":"10.1016\/j.canep.2026.103227_bib64","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1080\/10428194.2021.1929956","article-title":"Body mass index and survival of patients with lymphoma","volume":"62","author":"Chihara","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.canep.2026.103227_bib65","doi-asserted-by":"crossref","DOI":"10.1186\/s12877-019-1115-1","article-title":"Prevalence and overlap of sarcopenia, frailty, cachexia and malnutrition in older medical inpatients","volume":"19","author":"Gingrich","year":"2019","journal-title":"BMC Geriatr."}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782126002432?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782126002432?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:01:05Z","timestamp":1793419265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877782126002432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":65,"alternative-id":["S1877782126002432"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2026.103227","relation":{},"ISSN":["1877-7821"],"issn-type":[{"value":"1877-7821","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comorbidities in patients with lymphoma and their impact on clinical outcomes: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Cancer Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canep.2026.103227","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103227"}}